Recently, “Linezolid and Glucose Injection” (Brand name: Tianli), an antibacterial drug developed by the Group, has obtained the notice of approval of supplemental application on pharmaceutical product issued by the National Medical Products Administration of the People’s Republic of China, and passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs. Linezolid is used to cure the following infections caused by specific strains of susceptible microorganisms: hospital-acquired pneumonia, community-acquired pneumonia, complicated skin and soft tissue infections, uncomplicated skin and soft tissue infections, and vancomycin-resistant enterococcus faecium infection.
Linezolid is an oxazolidinone antibacterial drug. With its unique mechanism, linezolid is effective against a variety of clinically pathogenic Gram-positive (G+) bacteria, featuring the characteristics of broad antibacterial spectrum, strong body fluid and tissue penetration, high safety, etc., and has almost no cross-resistance to other antibacterial drugs (such as cephalosporins, quinolone or β-lactam antibiotics). It is widely used in respiratory, blood, intensive care units (ICU), tuberculosis/infection and other departments.
Yi Rui Da, another linezolid product of the Group that has previously passed the Consistency Evaluation, and Tianli have successively passed the Consistency Evaluation, which will be beneficial to the further market expansion of the Group’s linezolid products.